Once-Daily Niacin Extended Release/Lovastatin Combination Tablet Has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Than Atorvastatin and Simvastatin

Preventive Cardiology

Volumn 6, Issue 4, 2003, Pages 179-188

  Bays, Harold E ^a   McGovern, Mark E ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Kos Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERURICEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0242578512     PISSN: 1520037X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1520-037X.2003.03142.x     Document Type: Article

References (45)

1. Superko RH. Lipoprotein subclasses and atherosclerosis. Front Biosci. 2001;6:D355-D365.
2. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
3. Lamarche B, St-Pierre AC, Ruel IL, et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 2001;17:859-865.
4. Krauss RM, Stampfer MJ, Blanche PJ, et al. A prospective study of LDL particle diameter and risk of myocardial infarction [abstract 2469]. Circulation. 1994;90(part 2):I-460.
5. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
6. Griffin BA. Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc. 1999;58:163-169.
7. Griffin BA, Skinner ER, Maughan RJ. Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations. Atherosclerosis. 1988;70:165-169.
8. Johansson J, Carlson LA, Landou C, et al. High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb. 1991;11:174-182.
9. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18:1046-1053.
10. Kwiterovich PO Jr. Lipoprotein heterogeneity: diagnostic and therapeutic implications. Am J Cardiol. 2002;90:1i-10i.
11. Bays HE. Atherogenic dyslipidaemia in type 2 diabetes and metabolic syndrome: current and possible future treatment options. Br J Diabetes Vasc Dis. In press.
12. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.
13. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. 2003;91:667-672.
14. Bays HE. Combination niacin and statin therapy compared with monotherapy. Cardiol Rev. 2003;20(11):34-39.
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
16. Asztalos BF, Schaefer EJ. High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol. 2003;91:12E-17E.
17. Bittner V. Lipoprotein abnormalities related to women's health. Am J Cardiol. 2002;90:77i-84i.
18. Carr MC, Kim KH, Zambon A, et al. Changes in LDL density across the menopausal transition. J Investig Med. 2000;48:245-250.
19. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 1992;12:1496-1502.
20. Selby JV, Austin MA, Newman B, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation. 1993;88:381-387.
21. Zambon A, Hokanson JE, Brown BG, et al. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 1999;99:1959-1964.
22. Schaefer EJ, McNamara JR, Tayler T, et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol. 2002;90:689-696.
23. Isaacsohn J, Hunninghake D, Schrott H, et al. The effects of simvastatin in patients with hypertriglyceridemia [abstract]. Presented at: European Atherosclerosis Society 71st Congress; May 26-29, 1999, Athens, Greece
24. Kontopoulos AG, Athyros VG, Papageorgiou AA, et al. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis. 1996;7:843-850.
25. Otvos JD, Shalaurova I, Freedman DS, et al. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 2002;160:41-48.
26. Superko HR, Krauss RM, DiRicco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol. 1997;80:78-81.
27. Illingworth DR, Crouse JR III, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001;17:43-50.
28. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003;107:1733-1737.
29. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947-952.
30. Superko HR., Kos Investigators. Effect of nicotinic acid on LDL subclass patterns [abstract 2711]. Circulation. 1994;90(4 pt 2):I-504.
31. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 1992;95:69-76.
32. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol. 2003;91:1432-1436.
33. Tavintharan S, Kashyap ML. The benefits of niacin in atherosclerosis. Curr Atheroscler Rep. 2001;3:74-82.
34. McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001;88:270-274.
35. Bays H. Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol. 2002;90:30K-43K.
36. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
37. Elam MB, Hunninghake DB, Davis KB, et al., for the ADMIT Investigators. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA. 2000;284:1263-1270.
38. Grundy SM, Vega GL, McGovern ME, et al., for the Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med. 2002;162:1568-1576.
39. Van JT, Pan J, Wasty T, et al. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol. 2002;89:1306-1308.
40. Canner PI, Furberg CD, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the Coronary Drug Project [abstract 3138]. Circulation. 2002;106(suppl II):II-636.
41. Canner PL, Furberg CD, Terrin ML, et al. Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: results from the Coronary Drug Project [abstract 845-2]. J Am Coll Cardiol. 2003;41 (suppl A):291A.
42. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
43. Canner PL, Berge KG, Wenger NK, et al., for the Coronary Drug Project Research Group. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
44. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
45. Downs JR, Clearfield M, Weis S, et al., for the Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.